Skip to main content
NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
14.88
+0.74 (5.24%)
Nov 5, 2024, 3:49 PM EST - Market open

NeoGenomics Revenue

NeoGenomics had revenue of $167.82M in the quarter ending September 30, 2024, with 10.44% growth. This brings the company's revenue in the last twelve months to $644.12M, up 12.06% year-over-year. In the year 2023, NeoGenomics had annual revenue of $591.64M with 16.07% growth.

Revenue (ttm)
$644.12M
Revenue Growth
+12.06%
P/S Ratio
2.77
Revenue / Employee
$306,723
Employees
2,100
Market Cap
1.91B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023591.64M81.92M16.07%
Dec 31, 2022509.73M25.40M5.24%
Dec 31, 2021484.33M39.88M8.97%
Dec 31, 2020444.45M35.62M8.71%
Dec 31, 2019408.83M132.09M47.73%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Patterson Companies 6.53B
National HealthCare 1.17B
NovoCure 577.74M
BioCryst Pharmaceuticals 382.24M
Beam Therapeutics 352.57M
Galapagos NV 290.09M
Tarsus Pharmaceuticals 83.37M
Nurix Therapeutics 56.42M
Revenue Rankings

NEO News

More News